NASDAQ:CAPR Capricor Therapeutics Q3 2026 Earnings Date & Estimates $8.60 -0.32 (-3.59%) Closing price 11/5/2026 04:00 PM EasternExtended Trading$8.66 +0.06 (+0.76%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Capricor Therapeutics is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 10, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Capricor Therapeutics in Q3 2026Capricor Therapeutics is expected to post earnings of -$0.61 per share on revenue of $41.71 million. In the same quarter a year earlier Capricor Therapeutics reported -$0.54 per share. Capricor Therapeutics last reported on August 13, 2026, posting -$0.70 per share and missing the -$0.5889 consensus estimate. Capricor Therapeutics has beaten the consensus EPS estimate in 1 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.61Expected Revenue$41.71 millionPrior-Year EPS-$0.54Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.70 (Missed by -$0.1111)EPS Beat Rate1 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Capricor Therapeutics Q3 2026 Earnings FAQ When does Capricor Therapeutics report Q3 2026 earnings? Capricor Therapeutics (NASDAQ:CAPR) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Capricor Therapeutics' Q3 2026 earnings call? Capricor Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Capricor Therapeutics? Analysts expect Capricor Therapeutics to post earnings of -$0.61 per share for Q3 2026. How much revenue is Capricor Therapeutics expected to report? The consensus revenue estimate for Capricor Therapeutics is $41.71 million for Q3 2026. Capricor Therapeutics Earnings HeadlinesCAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For DeramiocelNovember 3 at 10:12 PM | finance.yahoo.comCapricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10November 3 at 12:09 PM | markets.businessinsider.comDollar Reset – Are You Prepared?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected. | Porter & Company (Ad)FDA decision watch: Regeneron and Roche’s autoimmune drugs, Capricor’s DMD therapy in spotlightNovember 2, 2026 | msn.comCAPR stock rallies into FDA decision month: Retail spots approval 'tea leaves' in Capricor's launch team hiringNovember 2, 2026 | msn.comCAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision NearsOctober 21, 2026 | msn.comSee More Capricor Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Capricor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capricor Therapeutics and other key companies, straight to your email. Email Address About Capricor TherapeuticsCapricor Therapeutics (NASDAQ:CAPR) is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage. Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials. Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners. The company is led by Linda Marbán, Ph.D., who serves as president and chief executive officer.View Capricor Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to WatchQualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a CatchUber's Profit Drop: A Speed Bump or Structural Shift?Boeing Has the Orders, the Cash Flow, and Insider Buyers, But What's Still Missing?Keurig Dr Pepper's Beverage Growth Raises a Tough Question About Its Coffee SplitAmazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Datadog's Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
